Plain-English translation of NCT07298434 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new preventive treatment called VYD2311, which is a type of medication designed to block the virus that causes COVID-19 from infecting your cells. Researchers want to see if VYD2311 can help prevent people from catching COVID-19 in the first place. You would receive either the medication or a placebo (saltwater injection) as three shots over three months.
COVID-19 continues to cause serious illness in many people, and researchers are looking for new ways to prevent infection beyond vaccines. This medication could offer an additional protection option for people who need it.
You would receive three injections into your upper arm or thigh—one on Day 1, one on Day 30, and one on Day 60. Some participants will receive the new medication at all three visits, some will receive it only on Day 1 and then placebo for the next two visits, and others will receive only placebo injections. The study lasts about 90 days after your first injection, and you'll have blood drawn at certain times to check how well the medication works and how your body responds to it.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States